KROS compared with RMR: revenue, margins and what each company keeps, and the suppliers and customers both name

KROSKeros Therapeutics, Inc.

Mkt capRevenueRevenue

RMRRMR Group Inc.

Mkt capRevenueRevenue

Compare

KROSKeros Therapeutics, Inc.

RMRRMR Group Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

KROS

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±25.5%▲+1.38%×0.05

May 14 '26±32.2%▼−8.34%×0.26

Q1 FY26±12.0%▼−14.96%×1.25

Nov 6 '25±16.3%▲+3.32%×0.20

RMR

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±6.7%▼−0.79%×0.12

Q2 FY26±4.1%▼−1.22%×0.29

= impliedKROS realized, solidRMR realized, hatchedOne scale, both sides: full bar = 33%× = |realized| ÷ impliedSource: market data

Q1 FY26

±7.0%

▲+7.59%

×1.09

Nov 13 '25±8.5%▲+0.51%×0.06

KROSKeros Therapeutics, Inc.

11.04· pre 10.73· delayed

Mkt cap$213.3MRevenue$367,000Q1 FY26Revenue$244MFY25

RMRRMR Group Inc.

16.90· pre 16.76· delayed

Pre-marketNov 2 '26delayed

Mkt cap$534.5MRevenue$154MQ3 FY26Revenue$704MFY25

Compare

Pre-marketNov 2 '26delayed

KROSKeros Therapeutics, Inc.

RMRRMR Group Inc.

11.04pre 10.73delayed

Price

16.90pre 16.76delayed

$213.3M

Mkt cap

$534.5M

Q1 FY26$367,000

Revenue

$154MQ3 FY26

FY25$244M

Revenue

$704MFY25

KROS11.04vsRMR16.90Pre-marketNov 2 '26delayed